7 completed, 6 unknown, 4 recruiting, 2 not yet recruiting. 20 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 20 | Completed 7, Unknown 6, Recruiting 4, Not yet recruiting 2, Enrolling by invitation 1 |
Follow Adrenocortical Hyperfunction: new trials by email Literature Review of Adrenocortical Hyperfunction trials Research Report on Adrenocortical Hyperfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPIRO-First: A Pragmatic Primary Care-Embedded Pilot Trial of Renin-Guided First-Line Antihypertensive Therapy Spironolactone (drug), Candesartan 8mg, Hydrochlorothiazide (HCTZ) 25 milligrams. - Hypertension | Phase 4 | Not yet recruiting | Ottawa Hospital Research Institute | 30 | 2027-01-01 | 2026-10-14 |
| Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome Osilodrostat, Placebo - Hypertension, Hypercortisolemia | Phase 4 | Recruiting | RECORDATI GROUP | 63 | 2026-08-26 | 2026-10-28 |
| Effects of Glucocorticoid Therapy on Renal Function in Patients With PA Complicated by CKD After Adrenalectomy: A Multicenter RCT Intervention_1 - Primary Aldosteronism Due to Adrenal Hyperplasia | Phase 4 | Not yet recruiting | Ruijin Hospital | 90 | 2026-04-22 | 2026-04-30 |
| Statin Combined with Amlodipine Treats Primary Aldosteronism Simvastatin combined with Amlodipine besylate, Simvastatin combined with Spironolactone and Amlodipine besylate., Amlodipine besylate combined Spironolactone - Primary Aldosteronism, Statin | Phase 4 | Recruiting | Third Military Medical University | 180 | 2024-09-10 | 2024-11-22 |
| Finerenone for Patients With Primary Aldosteronism (FAIRY) Finerenone Oral Tablet, Spironolactone Oral Tablet - Primary Aldosteronism | Phase 4 | Completed | Chongqing Medical University | 306 | 2024-06-04 | 2026-09-25 |
| The Clinical Efficacy and Safety of Finerenone in the Treatment of Primary Aldosteronism Finerenone - Primary Aldosteronism, Finerenone | Phase 4 | Completed | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 55 | 2024-03-01 | 2025-09-10 |
| Efficacy and Safety of Finerenone vs. Spironolactone in Patients With Primary Aldosteronism Finerenone, Spironolactone - Primary Aldosteronism | Phase 4 | Unknown | Shanghai Jiao Tong University School of Medicine | 150 | 2023-12-16 | 2023-12-11 |
| Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome Intervention/Treatment - Endogenous Cushing Syndrome | Phase 4 | Unknown | Centre hospitalier de l'Université de Montréal (CHUM) | 7 | 2023-10-24 | 2023-11-14 |
| Efficacy and Safety of Finerenone in Patients With Primary Aldosteronism finerenone - Primary Aldosteronism | Phase 4 | Completed | Chongqing Medical University | 60 | 2023-06-21 | 2024-06-18 |
| Comparing the Efficacy and Safety of Finerenone and Spironolactone in the Treatment of Primary Aldosteronism Finerenone, Spironolactone - Primary Aldosteronism, Hypertension | Phase 4 | Unknown | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 96 | 2023-05-01 | 2023-04-18 |
| Effect of MRA on Cardiovascular Disease in Patients With Hypertension and Hyperaldosteronemia Mineralocorticoid Receptor Antagonists(MRAs), Blank control - Hypertension, Hyperaldosteronaemia | Phase 4 | Enrolling by invitation | Nanfang Li | 8000 | 2023-04-16 | 2023-04-18 |
| Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST) Mifepristone 300 MG [Korlym], Placebo for mifepristone - Hypercortisolism, Diabetes Mellitus, Type 2 | Phase 4 | Completed | Corcept Therapeutics | 1113 | 2023-03-31 | 2025-01-20 |
| Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study Eplerenone - Primary Aldosteronism, Hypertension | Phase 4 | Recruiting | Brigham and Women's Hospital | 40 | 2022-12-15 | 2026-10-15 |
| MR Antagonist and LSD1 Eplerenone, Amlodipine - Hypertension, Mineralocorticoid Excess | Phase 4 | Completed | Brigham and Women's Hospital | 300 | 2022-02-03 | 2026-10-01 |
| Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's Syndrome Metarapone, Standardized antihypertensive therapy - Adrenal Incidentalomas, Cushing Syndrome | Phase 4 | Recruiting | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 50 | 2021-02-23 | 2025-01-30 |
| Influence of Synacthen Infusion on the Results of Adrenal Venous Sampling in Patient With Primary Aldosteronism Synacthen infusion during adrenal venous sampling - Primary Aldosteronism | Phase 4 | Unknown | Charles University, Czech Republic | 40 | 2011-03-01 | 2014-05-01 |
| Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? Eplerenone, Placebo - Hypertension, Dialysis | Phase 4 | Unknown | Shaare Zedek Medical Center | 27 | 2007-11-01 | 2007-11-06 |
| The Therapeutic Effect of Bromocriptin in Patients With Primary Aldosteronism bromocriptine - Hyperaldosteronism, Hypertension | Phase 4 | Unknown | National Taiwan University Hospital | 25 | 2007-01-01 | 2007-03-23 |
| Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy Posterior RA, Lateral transperitoneal LA - Adrenal Tumor, Pheochromocytoma | Phase 4 | Completed | Jagiellonian University | 65 | 2006-01-01 | 2013-10-10 |
| Kallikrein-kinin (KKS) and Renin-angiotensin-aldosterone System (RAAS) in Primary Aldosteronism captopril, Losartan (drug) - Hyperaldosteronism | Phase 4 | Completed | National Taiwan University Hospital | 100 | 2002-07-01 | 2014-12-17 |
Hyperaldosteronism (16) · Hypertension (11) · Cushing Syndrome (5) · ACTH Syndrome, Ectopic (2) · Adrenal Gland Neoplasms (1) · Adrenal incidentaloma (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Pheochromocytoma (1)
Adrenal Gland Diseases (20) · Endocrine System Diseases (20) · Cardiovascular Diseases (11) · Vascular Diseases (11) · Neoplasms (3) · Paraneoplastic Endocrine Syndromes (2) · Paraneoplastic Syndromes (2) · Endocrine Gland Neoplasms (1) · Glucose Metabolism Disorders (1) · Metabolic Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Germ Cell and Embryonal (1) · Neoplasms, Nerve Tissue (1)
Spironolactone (5) · finerenone (5) · Amlodipine (3) · Eplerenone (3) · Mineralocorticoid Receptor Antagonists (2) · Pharmaceutical Preparations (2) · Bromocriptine (1) · Captopril (1) · Hydrochlorothiazide (1) · Losartan (1) · Methods (1) · Mifepristone (1) · Nifedipine (1) · Osilodrostat (1) · Therapeutics (1)
Brigham and Women's Hospital (2) · Chongqing Medical University (2) · National Taiwan University Hospital (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Charles University, Czech Republic (1) · Corcept Therapeutics (1) · IRCCS Azienda Ospedaliero-Universitaria di Bologna (1) · Jagiellonian University (1) · Nanfang Li (1) · Ottawa Hospital Research Institute (1) · RECORDATI GROUP (1) · Ruijin Hospital (1) · Shaare Zedek Medical Center (1) · Shanghai Jiao Tong University School of Medicine (1)
China (6) · United States (4) · Canada (2) · Taiwan (2) · Czechia (1) · Israel (1) · Italy (1) · Poland (1)
Ping Li (2) · Vin-Cent Wu, MD (2) · Andrea Haas, MD (1) · Daniel Einhorn, MD (1) · Gregory L Hundemer, MD (1) · Guido Di Dalmazi, MD (1) · Irina Bancos, MD (1) · Jiguang Wang, MD. PhD (1) · Jiri Ceral, MD (1) · Kwan-Dun Wu, MD, PhD (1) · Kwan-Dun Wu, Md, PhD (1) · Linda Shavit, MD (1) · Qifu Q Li, PhD (1)
PMID 25052724, PMID 25243546, PMID 26414968, PMID 28822744, PMID 29129575, PMID 30077215, PMID 32418495, PMID 39013654, PMID 41568520
2025 (1)